NCT06703021CompletedPhase 2
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Efficacy of Increasing Optimal Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity (ACCESS II)
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (actual)
- First submitted
- 15 Nov 2024
- Start date
- 20 Dec 2024
- Primary completion date
- 12 Jan 2026
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Diseases
- Obesity
- NCT number
- NCT06703021
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 85
- From 20 Dec 2024 to the primary completion date, 12 Jan 2026
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous documented diagnosis of diabetes mellitus
- Self-reported change in body weight \>5% within 3 months before Screening
- Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
- Use of medications intended to promote weight loss, within 6 months prior to Screening
Who the study is looking for
- Signed informed consent
- BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| - Coordinator of this site? Confirm its status | East Greenwich | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Glendale | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Medford | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Montclair | United States | Unknown status |
| - Coordinator of this site? Confirm its status | North Charleston | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Valparaiso | United States | Unknown status |
| - Coordinator of this site? Confirm its status | West Des Moines | United States | Unknown status |
| - Coordinator of this site? Confirm its status | West Jordan | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.